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Abstract
Given the rapid development of genetic tests, an assessment of their beneﬁts, risks, and limitations is crucial for public health
practice. We performed a systematic review aimed at identifying and comparing the existing evaluation frameworks for
genetic tests. We searched PUBMED, SCOPUS, ISI Web of Knowledge, Google Scholar, Google, and gray literature
sources for any documents describing such frameworks. We identiﬁed 29 evaluation frameworks published between 2000
and 2017, mostly based on the ACCE Framework (n= 13 models), or on the HTA process (n= 6), or both (n= 2). Others
refer to the Wilson and Jungner screening criteria (n= 3) or to a mixture of different criteria (n= 5). Due to the widespread
use of the ACCE Framework, the most frequently used evaluation criteria are analytic and clinical validity, clinical utility
and ethical, legal and social implications. Less attention is given to the context of implementation. An economic dimension
is always considered, but not in great detail. Consideration of delivery models, organizational aspects, and consumer
viewpoint is often lacking. A deeper analysis of such context-related evaluation dimensions may strengthen a comprehensive
evaluation of genetic tests and support the decision-making process.
Introduction
The increased availability of genetic tests has made the
assessment of their performance crucial for clinical and
public health practice. However, the evaluation of genetic
tests, especially predictive ones, is not straightforward. The
main challenge is the lack of scientiﬁc evidence on which to
base such evaluations [1]. Generating scientiﬁc evidence on
genetic tests is made difﬁcult by different factors including
their complexity, their rapid development and marketing,
their widespread impact on families and society, and the
lack of standardized outcomes for their evaluation [1]. For
predictive genetic tests, perhaps the greatest challenge is to
perform high quality, randomized control trials to demon-
strate that the test confers an improvement in survival or
quality of life [2]. Moreover, the lack of evidence on
effectiveness affects the evaluation of cost-effectiveness.
Despite this, several frameworks have been proposed for
the evaluation of genetic tests, but it is unclear how and in
what respect they differ. The importance of a transparent and
well-planned evaluation strategy is twofold. On the one hand,
it would avoid the uncontrolled implementation of technolo-
gies without proven beneﬁts, which can lead to inappropriate
management of patients and detrimental effects on patient
health, as well as a waste of resources and loss of public
conﬁdence in the medical profession. On the other hand, in
line with the requirement for public health programs to max-
imize population health benefıts, a reliable evaluation strategy
would support the implementation of those currently available
tests that have proven effectiveness and cost effectiveness [3].
To guide the appropriate translation of genomics into
clinical practice, Italy developed a National Plan for Public
Health Genomics, which, to our knowledge, is the ﬁrst
speciﬁc policy example of its kind in Europe. It has various
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strategic objectives including the development of a well-
planned evaluation strategy for genetic tests [4]. Our sys-
tematic review was conducted as part of a project ﬁnanced
by the Italian Ministry of Health to implement this plan and
aims to identify and compare the existing evaluation fra-
meworks for genetic tests, taking into account their meth-
odology and evaluation criteria.
Materials and methods
This review was performed according to the Cochrane
Handbook for systematic reviews of intervention and the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [5, 6].
Selection criteria
We included any document that describes an original
evaluation framework for genetic tests, deﬁned as a
structured process for the collection of the scientiﬁc
evidence needed to assess the performance of a genetic
test, from the laboratory to clinical practice. We excluded
partial evaluation frameworks, deﬁned as those embracing
less than three evaluation components (analytic validity,
clinical effectiveness, etc.). We limited our search to fra-
meworks speciﬁcally created for the evaluation of genetic
tests.
Search methods
Two reviewers (EP and CD) searched the bibliographic
databases Pubmed, Scopus, ISI Web of Knowledge, Google
Scholar, and the world wide web through Google for all
English language articles between January 1990 and April
2017. The search terms were grouped as two strings: String
A, “genetic testing OR genetic test OR genomic test OR
genomic technology OR pharmacogenetic test” AND “eva-
luation OR assessment OR evaluating OR assessing OR
evaluate OR assess” AND “framework OR criteria OR tool
OR model OR process OR methods OR evidence based”
OR “analytic validity OR clinical validity OR clinical uti-
lity”; and String B, “genetic testing OR genetic test OR
genomic test OR genomic technologies OR pharmacoge-
netic test OR public health genomics OR pharmacogenetics
OR pharmacogenomics” AND “health technology assess-
ment” (see Supplementary Information for the full electronic
search for each database). This search was supplemented by
exploring the websites of government agencies and research
organizations involved in the evaluation of genetic tests
(see Supplementary Information for a list of the respective
websites) and by scanning the reference lists of all the
relevant articles retrieved. Moreover, experts of the Italian
Network of Public Health Genomics were asked to share the
evaluation frameworks they were aware of through a Delphi
procedure.
Study selection
The two reviewers (EP and CD) removed duplicates and
screened the title and abstract of all retrieved records. Stu-
dies that clearly did not meet the eligibility criteria were
excluded. Full texts of potentially relevant studies were
examined for inclusion in the systematic review and reasons
for exclusion recorded. Disagreements were resolved by
discussion.
Data collection and analysis
Two reviewers (EP and EDA) extracted the following
information about the retrieved frameworks: authors;
country; year of publication; reference institution; frame-
work name; type of target test; reference frameworks;
methodology (format, sources of evidence, quality of the
evidence, grading of recommendations, research priorities);
practical application; purpose; primary audience; evaluation
components (see Supplementary Information for a deﬁni-
tion of each category of information extracted). A narrative
synthesis of the evaluation frameworks identiﬁed was per-
formed, comparing their general features, evaluation com-
ponents, and methodological aspects.
Results
Study selection
After removal of duplicates, 6027 records resulted from the
initial search (Fig. 1). Screening by title and abstract
selected 289 records for full text analysis, from which 30
records were selected. Reasons for exclusion were: docu-
ments not describing a framework for the evaluation of
genetic tests; appraisals of individual genetic tests using an
original framework described elsewhere; partial evaluation
frameworks; documents focusing on only one evaluation
component; broader frameworks of implementation
research not proposing an original evaluation process;
guidelines on the evaluation of genetic tests; reviews and
commentaries of evaluation frameworks and evaluation
criteria for genetic tests; full text not available. Six records
were added to the previous 30 from the reference lists of
relevant articles retrieved. A total of 36 records were
included in the systematic review, describing 29 frame-
works for the evaluation of genetic tests (some records
describe the same framework) [7–42]. The Delphi proce-
dure did not add new frameworks to those already retrieved.
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Frameworks retrieved
The systematic search identiﬁed 29 frameworks from var-
ious countries (USA, n= 12; Canada, n= 4; Europe, n= 9;
Australia, n= 2; international, n= 2) published between
2000 and 2017 (Table 1).
The majority are based on the ACCE Framework (whose
name derives from the evaluation components used: ana-
lytic validity, clinical validity, clinical utility, ethical, legal
and social implications) (n= 13) [7–24], on the Health
Technology Assessment (HTA) process (n= 6) [25–31], or
both (n= 2) [32, 33]. The remaining frameworks refer to
the Wilson and Jungner screening criteria (n= 3) [34–37],
or to a mixture of preexisting frameworks, which are not
necessarily speciﬁc for genetic tests, even if the ACCE
framework is often included (n= 5; Table 1) [38–42].
Seventeen frameworks deal with genetic tests in general
[7–19, 22, 26, 27, 32, 36–42]; ﬁve refer to genetic sus-
ceptibility tests [20, 24, 33–35]; three to pharmacogenetic
tests [23, 30, 31]; two to predictive genetic tests (including
susceptibility and presymptomatic tests) [25, 28]; one to the
new technologies of personalized medicine [29] and another
to newborn screening [21] (see Supplementary Information
for deﬁnitions of types of test) (Table 1). Most of the fra-
meworks pursue a wider aim than simply summarize evi-
dence, for example, support provision and coverage
PUBMED records
String A N=3817
String B N=133
N=3950
SCOPUS records
String A N=782
String B N=303
N=1085
ISI WOS records
String A N=2561
String B N=35
N=2596
Google Scholar
records
String A N=150
String B N=150
N=300
Other sources
Google N=68
Selected websites N=37
N=105
Records after
duplicates removed
N=6027
Selected articles
screened by TITLE
and ABSTRACT
N=289
Full text articles
assessed for
eligibility
N=281
Duplicates removed
N=8
Records screened by
TITLE and ABSTRACT
and excluded
N=5738
Articles included in
the review
N=36
Additional records
added from
reference lists
N=6
Original evaluation
frameworks
N=29
Full text articles excluded with reasons
- No evaluation framework for genetic
tests N=115
- Application of an evaluation framework
N=27
- Partial framework N=4
- One evaluation component N=42
- Broader framework of implementation
N=6
- Guidelines N=4
- Review and commentaries N=32
- Full text not available N=21
N=251
Fig. 1 PRISMA ﬂow diagram of
the review process
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decisions or guide clinical practice; the intended primary
audience is mainly represented by decision/policy makers
(Table 1).
In addition to the two frameworks created as appraisal
tools for individual genetic tests (HTA Pharmacogenetics
and HTA Susceptibility Test) [31, 33], 11 frameworks were
used to generate reports that are available on the web (all
open access, except Hayes GTE reports) (Table 1) [43–54].
The most productive frameworks are the Evaluation of
Genomic Applications in Practice and Prevention (EGAPP)
Process (11 evidence reports and 10 recommendations), the
GFH Card (46 cards), the Clinical Utility Gene Card (about
136 cards), and the NHS UKGTN Gene Dossier (476
dossiers) [44, 45, 47–49].
Evaluation components
The most-represented evaluation components in the
retrieved frameworks are analytic validity (included in 93%
of retrieved frameworks), clinical validity (96%), clinical
utility (100%), economic validity (100%), and ethical, legal,
and social implications (ELSI) (76%). The analysis of these
components is usually introduced by an overview of the
disease and the test under study (86%). Evaluation com-
ponents frequently missing from the evaluation frameworks
are organizational aspects (lacking in 48% of retrieved
frameworks), delivery models (73%), and the patient/citi-
zen’s point of view (93%) (Table 2).
Analytic validity is the ability of the test to accurately
and reliably measure the genotype of interest [55]. It is
considered in markedly different ways in 27 retrieved fra-
meworks (Table 2) [7–28, 30–34, 36–42]. It is most fre-
quently addressed in terms of sensitivity and speciﬁcity, but
assay robustness and quality assurance, including internal
and external control programs, are often considered (e.g.,
ACCE, EGAPP) [7, 11, 12]; some frameworks (e.g.,
Expanded ACCE, SynFRAME) extend the concept using
more criteria [15, 39].
Clinical validity is the ability of the test to accurately and
reliably detect or predict a clinical condition [55]. It is
considered in 28 retrieved frameworks (Table 2) [7–28, 30–
42]. The majority identify clinical validity as test perfor-
mance and measure it in terms of sensitivity, speciﬁcity, and
positive and negative predictive value. Other frameworks
(e.g., Expanded ACCE, Complex Diseases) preface the
evaluation of the performance of the test with explicit
evaluation of the scientiﬁc validity, that is, the evidence of
gene–disease association, which is usually expressed as an
odds ratio or relative risk [15, 20].
Clinical utility, in its narrowest sense, compares the risks
and beneﬁts of testing and provides evidence of clinical
usefulness for the integrated package of care in terms of
measurable health outcomes [56]. It is considered in all 29
frameworks retrieved, with a certain heterogeneity (Table 2)
[7–42]. Some frameworks (e.g., HTA Personalized Health
Care, HTA Pharmacogenetics) embrace the narrow deﬁni-
tion of clinical utility and consider only efﬁcacy, effec-
tiveness, and safety [29, 31]. Others extend the concept and
Table 2 Evaluation components and methodological aspects
considered in the retrieved evaluation frameworks
N (29) % Reference
Evaluation components
Overview disease/test under
study
25 86 [7–22, 24, 25, 27, 29–
34, 36–42]
Analytic validity 27 93 [7–28, 30–34, 36–42]
Clinical validity 28 96 [7–28, 30–42]
Clinical utility 29 100 [7–42]
Ethical, legal, and social
implications
22 76 [7–15, 20–22, 25–29,
32–40, 42]
Delivery models 8 27 [13, 24, 29, 30, 34–38]
Organizational aspects 15 52 [7–10, 13, 14, 24–30,
32, 34–38]
Economic evaluationa 29 100 [7–42]
Patient/citizen’s point of
viewb
2 7 [15, 33]
Methodological aspects
Format
Key questions 12 41 [7, 11–15, 20–23, 32,
41, 42]
Card 5 17 [8–10, 16–19, 24, 25]
Checklist 2 7 [30, 38]
Set of principle/
methodological guidance
10 34 [26–29, 31, 33–37, 39,
40]
Evidence collection and evaluation
Source of evidencec 13 45 [7, 11–15, 21, 22, 25,
30, 31, 33, 39, 42]
Quality of the evidenced 12 41 [11–14, 21, 22, 25, 30,
31, 33, 35, 39, 42]
Evidence gaps/research
priorities
12 41 [7, 11, 12, 14, 21, 23,
25, 28, 31, 34, 38, 40,
42]
Recommendations 5 17 [11, 12, 21, 28, 32, 42]
Note: where it was unclear whether an evaluation component was
present, it was considered missing and the methodological aspect
unfulﬁlled
aEconomic evaluation: the evaluation component was considered as
present in the evaluation framework even if only a cost-analysis, and
not a complete economic evaluation, was mentioned
bPatient/citizen’s point of view: the evaluation component was counted
only if a direct reference to patient consultation was made
cSource of evidence: the methodological aspect was considered
fulﬁlled even if the topic of the source of evidence was given only a
brief mention without further details
dEvaluation of quality of the evidence: the methodological aspect was
considered fulﬁlled even if the topic of the quality of evidence was
only mentioned brieﬂy without details of the criteria used to assess the
quality
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include considerations of aspects otherwise evaluated
independently from clinical utility, such as organizational
aspects, cost-effectiveness analysis, and ELSI (e.g., ACCE,
Expanded ACCE, ACHDNC) [7, 15, 21]. The broadening
of the perception of beneﬁts reaches its greatest extent in the
concept of personal utility, adopted in some frameworks
(e.g., Complex Diseases, ACHDNC), that is, the full range
of personal effects that the test may have on patients, such
as improved understanding of the disease, enabling repro-
ductive choices or risk-reducing behaviors [20, 21, 57].
The economic evaluation of genetic tests involves the
comparative analysis of both the costs and consequences of
the various tests under study [58]. All 29 frameworks
retrieved consider the economic dimension, but not always
in great detail (Table 2) [7–42]. Many models address the
cost-effectiveness of the test under study only in the most
general terms (e.g., ACCE), and only a few involve precise
quantitative and qualitative evaluations of cost-effectiveness
and cost-utility evidence (e.g., Codependent Technologies,
SynFrame) [7, 30, 39]; other frameworks consider only the
ﬁnancial aspects, either in terms of the cost of the inter-
vention or related savings (e.g., NHS UKGTN Gene Dos-
sier, PACNPGT) [8–10, 25].
The ELSI evaluation component is concerned with the
moral value that society confers on the proposed interven-
tions, the speciﬁc related legal norms and the impact on the
social life of the patient and his or her family [55]. They are
considered in 22 retrieved frameworks and analyzed inde-
pendently (e.g., ACCE, Andalusian) or integrated into other
components of evaluation, such as clinical utility, as psy-
chosocial outcomes of testing (e.g., EGAPP, AETMIS
HTA) (Table 2) [7–15, 20–22, 25–29, 32–40, 42].
We deﬁned a delivery model for the provision of genetic
tests as the broad context in which genetic tests are offered
to individuals and families with or at risk of genetic dis-
orders. It includes the health care programs (any type of
health intervention preceding and following a genetic test),
the clinical pathways (the patient ﬂow through different
professionals during the testing process), and the level of
care (e.g., primary or specialist care level) in which the test
is delivered [59]. Although a complete description of the
delivery models is lacking in all frameworks retrieved, we
ascribe it to eight retrieved frameworks (Table 2): the three
screening frameworks, as they include the concept of health
care program [34–37], and ﬁve other frameworks, which
mentioned some of the elements, albeit not in detail
(Table 2) [13, 24, 29, 30, 38].
Organizational aspects include the human, material, and
economic resources needed to implement the genetic pro-
gram as well as the consequences of the implementation on
the organizations involved and the whole health care sys-
tem. Although they do not include a thorough feasibility
analysis, 15 retrieved frameworks attempt to estimate the
resources required to start up and maintain a particular
genetic testing service (Table 2) [7–10, 13, 14, 24–30, 32,
34–38].
The perspective of patients provides experiential evi-
dence that can be used in the evaluation process [60]. Only
two of the retrieved frameworks evaluate the direct
experience of the patient and other affected individuals, for
example, by their participation in surveys (Table 2) [15, 33].
One of these (Expanded ACCE) includes the patient per-
spective as part of the clinical utility component, whereas
the other (HTA Susceptibility Test) assigns it its own
dedicated section.
Methodological aspects
The most frequently used formats are the key questions
format (12 frameworks) [7, 11–15, 20–23, 32, 41, 42],
the card format (ﬁve frameworks) [8–10, 16–19, 24, 25],
and the checklist format (two frameworks) [30, 38].
The other frameworks have a less structured format
and resemble general manuals (Table 2) [26–29, 31, 33–37,
39, 40].
With respect to the process of evidence review, 13 fra-
meworks provide some indication, albeit in scant detail, of
the sources referred to [7, 11–15, 21, 22, 25, 30, 31, 33, 39,
42]; 12 frameworks provide an evaluation of the quality of
evidence, but the criteria adopted are not always stated
clearly [11–14, 21, 22, 25, 30, 31, 33, 35 39, 42]; and
ﬁnally 12 frameworks attempt to deal with evidence gaps
through the formulation of research priorities (Table 2) [7,
11, 12, 14, 21, 23, 25, 28, 31, 34, 38, 40, 42].
Only ﬁve of the retrieved frameworks provide, or at least
suggest, criteria for making recommendations based on the
evidence collected [11, 12, 21, 28, 32, 42]. The most fre-
quently used criteria are the magnitude of the net beneﬁt
and the level of certainty of the evidence.
Discussion
Our review identiﬁed three main approaches to the eva-
luation of genetic testing: the ACCE model, the HTA pro-
cess, and the Wilson and Jungner screening criteria. The
most popular is the ACCE model, developed in 2000 by the
US Centers for Disease Control and Prevention [7]. In 2004,
it was further developed to become EGAPP initiative, to
make recommendations for clinical and public health
practice [11, 12]. The UK Genetic Testing Network and the
Andalusian Agency for Health Technology Assessment re-
elaborated the ACCE model to guide the introduction of
new genetic tests into their public health system, creating
the 2004 NHS UKGTN Gene Dossier and the 2006
Andalusian Framework, respectively [8–10, 13]. In 2007,
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the ACCE model was reworked again: an expanded version
of ACCE, supported by the PHG Foundation, added health
quality measures to the evaluation process, whereas a more
streamlined version shortened the systematic review process
for emerging genetic tests [14, 15]. In 2010, the ACCE
model was applied to speciﬁc types of genetic test through
the Complex Disease Framework and the ACHDNC
Newborn Screening Framework of the Advisory Committee
on Heritable Disorders in Newborns and Children [20, 21].
The ACCE model also inspired two related European fra-
meworks, the 2008 GFH Indication Criteria of the German
Society of Human Genetics and the 2010 Clinical Utility
Gene Card of EuroGentest [16–19], the latter of which in
turn inspired the 2017 Australian Clinical Utility Card [24].
In 2011, the ECRI Institute used the EGAPP process to
develop a set of analytical frameworks for different testing
scenarios and stakeholder perspectives [22]. Finally, the
2015 Companion tests Assessment Tool (CAT) used the
ACCE model as a ﬁlter mechanism to determine which
tests, in which speciﬁc areas, required evaluation [23]. Our
results show that the ACCE framework is the main con-
ceptual frame for the evaluation of genetic tests and the
most used in practice, as it inspired very productive fra-
meworks in terms of evidence reports such as the EGAPP,
the Clinical Utility Gene Card, and the NHS UKGTN Gene
Dossier. Some attempts have been made to merge the
ACCE and the HTA model, for example, the 2009 frame-
work for genetic tests used by the private American com-
pany Hayes and the 2012 framework for susceptibility tests
ﬁnanced by the Italian Ministry of Education, Universities
and Research [32, 33].
Due to the widespread use of the ACCE framework, the
most frequently employed evaluation components are ana-
lytic validity, clinical validity, clinical utility, and ELSI.
Although these evaluation components clearly address the
technical value of a genetic test, less attention is given to the
wider context. Thus, although the clinical context is given
sufﬁcient consideration in some cases, in particular the NHS
UKGTN evaluation process, whose testing criteria deﬁne
the appropriate clinical situations for use of a given test
[60], the broader context for implementation of a genetic
test is often disregarded. In fact, even where an economic
evaluation is performed, it is usually rather superﬁcial;
similarly, the analysis of delivery models and organizational
aspects, when presented, is usually not well structured.
These context-related evaluation components are more
often considered by the HTA-based evaluation frameworks.
The direct experience of patients is almost totally neglected.
Nevertheless, being patients the direct beneﬁciaries of a
genetic technology, their perspective could help under-
standing its value [61]. Finally, the criteria for making
recommendations on the clinical implementation of tests are
rarely explored.
Since decision makers are the main audience of the
evaluation process, the lack of attention to the context-
related evaluation components (delivery models, economic
evaluation, and organizational aspects) and to the
recommendation-making process are arguably the main
limitations of the retrieved frameworks. The analysis of the
context of implementation, peculiar to the HTA, is critical
for securing an efﬁcient and equitable allocation of health
care resources and services. An EU-funded research project
named HIScreenDiag [62], which closed in 2011, aimed to
assess genetic tests using the HTA methodology of the
European Network for Health Technology Assessment,
which includes a detailed analysis of the economic, orga-
nizational, and delivery aspects [63]. Moreover, the adop-
tion of an evidence grading system such as Grading of
Recommendations Assessment, Development and Evalua-
tion (GRADE), which scores the strength of recommenda-
tions after taking into consideration aspects like patient
values and use of resources, would help move the evalua-
tion process from evidence to implementation, and would
make the process more comprehensive [64]. Finally,
because these frameworks were mainly developed to
address single-gene testing, we might consider how
appropriate they are for tests based on next-generation
sequencing (NGS). However, frameworks that have been
adapted for NGS, such as the NHS UKGTN Gene Dossier
and the Clinical Utility Gene Card, have proved effective
[65, 66].
In contrast to our systematic review, the majority of
reviews in the literature on evaluation frameworks for
genetic tests have a narrative structure. The only three
systematic reviews we retrieved are described as methods
for the construction of an evaluation framework (ECRI,
SynFRAME, Practical Framework), so their methodology is
not strictly reported [22, 39, 40].
One limitation of our work might be a failure to retrieve
some of the studies published in the gray literature. To
maximize the sensitivity of the search, we used broad search
terms, but these yielded results with low speciﬁcity; how-
ever, we corrected this during the selection process.
Moreover, the comparison between the retrieved frame-
works could have been affected by the fact that not all
frameworks clearly deﬁned their evaluation components,
especially with respect to delivery models and organiza-
tional aspects.
In conclusion, the ACCE model proves to be a base for
the technical appraisal of genetic tests. However, this model
is not completely satisfying. We suggest the adoption of a
broader HTA approach, including the assessment of the
context-related evaluation dimensions (delivery models,
economic evaluation, and organizational aspects). This
approach would maximize population health beneﬁts,
facilitate decision-making and address the main challenges
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of the implementation of genetic tests, particularly in uni-
versal health care systems, where economic sustainability is
a major issue.
Acknowledgements This work is part of the Italian project “Deﬁni-
zione e promozione di programmi per il sostegno all’attuazione del
Piano d’Intesa del 13/3/13 recante Linee di indirizzo su La Genomica
in Sanità Pubblica (Deﬁnition and promotion of programs to support
the implementation of the Guidelines on Genomics in Public Health)”,
funded by the Italian Ministry of Health. This work is also partially
supported by the project “Personalized pREvention of Chronic Dis-
eases consortium (PRECeDI)” funded by the European Union’s Hor-
izon 2020 research and innovation programme MSCA-RISE-2014
(Marie Skłodowska-Curie Research and Innovation Staff Exchange),
under the grant agreement N°645740.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International License,
which permits any non-commercial use, sharing, distribution and
reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, and provide a link to the
Creative Commons license. You do not have permission under this
license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in
the article’s Creative Commons license, unless indicated otherwise in a
credit line to the material. If material is not included in the article’s
Creative Commons license and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy
of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Khoury MJ, Coates RJ, Evans JP. Evidence-based classiﬁcation of
recommendations on use of genomic tests in clinical practice:
dealing with insufﬁcient evidence. Genet Med. 2010;12:680–3.
2. Marzuillo C, De Vito C, D’Andrea E, Rosso A, Villari P. Pre-
dictive genetic testing for complex diseases: a public health per-
spective. QJM. 2014;107:93–97.
3. Khoury MJ, Bowen MS, Burke W, et al. Current priorities for
public health practice in addressing the role of human genomics in
improving population health. Am J Prev Med. 2011;40:486–93.
4. Boccia S, Federici A, Colotto M, Villari P. Implementation of
Italian guidelines on public health genomics in Italy: a challenging
policy of the NHS. Epidemiol Prev. 2014;38:29–34.
5. Higgins JPT, Green S (editors). Cochrane Handbook for Sys-
tematic Reviews of Interventions, version 5.1.0. The Cochrane
Collaboration, 2011.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement
for reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. J
Clin Epidemiol. 2009;62:e1–34. https://doi.org/10.1016/j.jclinepi.
2009.06.006.
7. Haddow JE, Palomaki GE. ACCE: a model process for evaluating
data on emerging genetic tests. In: Khoury M, Little J, Burke W
editors. Human genome epidemiology: a scientiﬁc foundation for
using genetic information to improve health and prevent disease..
Oxford, UK: Oxford University Press; 2004. p. 217–33.
8. UK Genetic Testing Network. Testing criteria for molecular
genetic tests. 2005. Available at http://ukgtn.nhs.uk/ﬁleadmin/
uploads/ukgtn/Documents/Resources/Library/Policies_
Procedures/MKTesting%20Criteria%20Paper%202005.pdf.
Accessed 26 Apr 2017.
9. Kroese M, Zimmern RL, Farndon P, Stewart F, Whittaker J. How
can genetic tests be evaluated for clinical use? Experience of the
UK Genetic Testing Network. Eur J Hum Genet. 2007;9:917–21.
10. UK Genetic Testing Network. First report of the UKGTN. Sup-
porting genetic testing in the NHS. London, UK: UK Genetic
Testing Network; 2008.
11. Teutsch SM, Bradley LA, Palomaki GE, et al. The evaluation of
genomic applications in practice and prevention (EGAPP) initia-
tive: methods of the EGAPP Working Group. Genet Med.
2009;1:3–14.
12. Veenstra DL, Piper M, Haddow JE, et al. Improving the efﬁciency
and relevance of evidence-based recommendations in the era of
whole-genome sequencing: an EGAPP methods update. Genet
Med. 2013;1:14–24.
13. Márquez Calderón S, Briones Pérez, de la Blanca E. Framework
for the assessment of genetic testing in the Andalusian Public
Health System. Seville, Andalusia: Andalusian Agency for Health
Technology Assessment; 2006.
14. Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid
ACCE: experience with a rapid and structured approach for
evaluating gene-based testing. Genet Med. 2007;7:473–8.
15. Burke W, Zimmern R. Moving beyond ACCE: an expanded
framework for genetic test evaluation. Cambridge, UK: PHG
Foundation; 2007.
16. Aretz S, Rautenstrauß B, Timmerman V. Indication criteria for
genetic testing. Evaluation of validity and clinical utility. Munich,
Germany: German Society of Human Genetics; 2008.
17. Schmidtke J, Cassiman JJ. The EuroGentest Clinical Utility Gene
Cards. Eur J Hum Genet. 2010;24:1. https://doi.org/10.1038/ejhg.
2010.85.
18. Dierking A, Schmidtke J, Matthijs G, Cassiman JJ. The Euro-
Gentest Clinical Utility Gene Cards continued. Eur J Hum Genet.
2013;21:1. https://doi.org/10.1038/ejhg.2012.161.
19. Dierking A, Schmidtke J. The future of Clinical Utility Gene
Cards in the context of next-generation sequencing diagnostic
panels. Eur J Hum Genet. 2014;22:1247. https://doi.org/10.1038/
ejhg.2014.23.
20. Wright CF, Kroese M. Evaluation of genetic tests for suscept-
ibility to common complex diseases: why, when and how? Hum
Genet. 2010;127:125–34.
21. Calonge N, Green NS, Rinaldo P, et al. Committee report: method
for evaluating conditions nominated for population-based
screening of newborns and children. Genet Med. 2010;3:153–9.
22. Sun F, Bruening W, Erinoff E, Schoelles KM, ECRI Institute
Evidence-based Practice Center. Addressing challenges in genetic
test evaluation. Evaluation frameworks and assessment of analytic
validity. Rockville, USA: Agency for Healthcare Research and
Quality; 2011.
23. Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra
DL. Improving the efﬁciency and quality of the value assessment
process for companion diagnostic tests: The Companion test
Assessment Tool (CAT). J Manag Care Spec Pharm.
2015;21:700–12.
24. Medical Service Advisory Committee. Australian Government,
Department of Health. Clinical Utility Card for heritable muta-
tions which increase risk in [disease area]. 2016. Available at
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/
9C7DCF1C2DD56CBECA25801000123C32/$File/CUC-
proforma-assessment-genetic-testing.pdf Accessed 18 Apr 2017.
25. Advisory Committee on New Predictive Genetic Technologies.
Genetic Services in Ontario: Mapping the Future. Report of the
How is genetic testing evaluated?
Provincial Advisory Committee on New Predictive Genetic
Technologies. Ontario, Canada: Advisory Committee on New
Predictive Genetic Technologies; 2001.
26. Blancquaert I, Bouchard L, Chikhaoui Y, Cleret, de Langavant G.
Molecular genetics viewed from the Health Technology Assess-
ment Perspective. Eur J Hum Genet. 2001;1:309–10. (abstract)
27. Blancquaert I. Testing for BRCA: the Canadian experience. In:
Kroese M, Elles R, Zimmern RL, editors. The Evaluation of
Clinical Validity and Clinical Utility of Genetic Tests, Summary
of an expert workshop, 26 and 27 June 2006. Cambridge, UK:
PHG Foundation; 2007. p. 23–25.
28. Giacomini M, Miller F, Browman G. Confronting the “gray zones”
of technology assessment: evaluating genetic testing services for
public insurance coverage in Canada. Int J Technol Assess Health
Care. 2003;2:301–16.
29. Gutiérrez-Ibarluzea I Personalised Health Care, the need for
reassessment. A HTA perspective far beyond cost-effectiveness.
Ital J Public Health. 2012; https://doi.org/10.2427/8653.
30. Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P.
Assessing personalized medicines in Australia: a national frame-
work for reviewing codependent technologies. Med Decis Mak.
2013;3:333–42.
31. Fleeman N, Martin Saborido C, Payne K, et al. The clinical
effectiveness and cost-effectiveness of genotyping for CYP2D6
for the management of women with breast cancer treated with
tamoxifen: a systematic review. Health Technol Assess.
2011;33:1–102.
32. Allingham-Hawkins DJ, Lea A, Spock L, Levine S Hayes Genetic
Test Evaluation (GTE) Program: Evidence-based evaluation of
genetic tests. Inaugural Meeting of the Genomic Applications in
Practice and Prevention Network. Ann Arbor, USA, 29-30 Oct
2009 (abstract).
33. Betti S, Boccia A, Boccia S, et al. HTA of genetic testing for
susceptibility to venous thromboembolism in Italiy. Ital J Public
Health. 2012; https://doi.org/10.2427/6348.
34. Goel V. Appraising organised screening programmes for testing
for genetic susceptibility to cancer. BMJ. 2001;7295:1174–8.
35. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Appli-
cation of population screening principles to genetic screening for
adult-onset conditions. Genet Test. 2001;3:201–11.
36. Andermann A, Blancquaert I, Beauchamp S, Costea I.
Guiding policy decisions for genetic screening: developing a
systematic and transparent approach. Public Health Genom.
2011;1:9–16.
37. Andermann A, Blancquaert I, Déry V. Genetic screening: a con-
ceptual framework for programs and policy-making. J Health Serv
Res Policy. 2010;2:90–97.
38. Rousseau F, Lindsay C, Charland M, et al. Development and
description of GETT: a genetic testing evidence tracking tool. Clin
Chem Lab Med. 2010;10:1397–407.
39. Hornberger J, Doberne J, Chien R. Laboratory-developed test--
SynFRAME: an approach for assessing laboratory-developed tests
synthesized from prior appraisal frameworks. Genet Test Mol
Biomark. 2012;6:605–14.
40. Lin JS, Thompson M, Goddard KA, Piper MA, Heneghan C,
Whitlock EP. Evaluating genomic tests from bench to bedside: a
practical framework. BMC Med Inform Decis Mak. 2012;12:117.
41. Frueh FW, Quinn B. Molecular diagnostics clinical utility strat-
egy: a six-part framework. Expert Rev Mol Diagn.
2014;14:777–86.
42. National Academies of Sciences, Engineering, and Medicine. An
evidence framework for genetic testing.. Washington, USA: The
National Academies Press; 2017.
43. Centers for Disease Control and prevention. First ACCE Review:
Population-based Prenatal Screening for Cystic Fibrosis via
CarrierTesting. 2002. Available at https://www.cdc.gov/genomics/
gtesting/acce/acce.htm. Accessed 26 Apr 2017.
44. UK Genetic Testing Network website. Available at http://ukgtn.
nhs.uk/ﬁnd-a-test/gene-dossiers. Accessed 8 May 2017.
45. Evaluation of Genomic Applications in Practice and Prevention
web site. Available at http://www.cdc.gov/egappreviews/. Acces-
sed 8 May 2017.
46. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE
review of CYP2C9 and VKORC1 alleles testing to inform war-
farin dosing in adults at elevated risk for thrombotic events to
avoid serious bleeding. Genet Med. 2008;2:89–98.
47. German Society of Human Genetics website. Available at
http://www.gfhev.de/de/leitlinien/Diagnostik_LL.htm. Accessed 8
May 2017.
48. EuroGentest website. Available at http://www.eurogentest.org/
index.php?id=668. Accessed 21 Sept 2017.
49. European Journal of Human Genetics website. Available at
http://www.nature.com/ejhg/archive/categ_genecard_012017.
html?lang=en. Accessed 8 May 2017.
50. Advisory Committee on Heritable Disorders in Newborns and
Children web site. Available at http://www.hrsa.gov/a
dvisorycommittees/mchbadvisory/heritabledisorders. Accessed
26 Aug 2017.
51. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of
genetic testing in adults with a history of venous thromboembo-
lism. Evidence Reports/Technology Assessments, No. 180.
Rockville, USA: Agency for Healthcare Research and Quality.
2009.
52. Medical Service advisory committee website. Available at
http://www.health.gov.au/internet/msac/publishing.nsf/Content/
1411-public. Accessed 05 Apr 2017.
53. Tranchemontagne J, Boothroyd L, Blancquaert I. Contribution of
BRCA1/2 Mutation Testing to Risk Assessment for Susceptibility
to Breast and Ovarian Cancer. Monograph. Montréal, Canada:
Agence d’évaluation des technologies et des modes d’intervention
en santé; 2006.
54. Hayes Inc. Genetic test evaluation website. Available at
https://www.hayesinc.com/hayes/publications/genetic-test-evalua
tion. Accessed 25 Apr 2017.
55. Zimmern RL, Kroese M. The evaluation of genetic tests. J Public
Health. 2007;29:246–50.
56. Grosse SD, Khoury MJ. What is the clinical utility of genetic
testing? Genet Med. 2006;8:448–50.
57. Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic
testing: a systematic literature review. Eur J Hum Genet.
2017;25:662–8. https://doi.org/10.1038/ejhg.2017.10.
58. Drummond MF, Sculpher MJ, Claxton K, Torrance GW, Stoddart
GL, editors. Methods for the economic evaluation of health care
programmes. 4th edn. Oxford, UK: Oxford University Press;
2015.
59. D’Andrea E, Marzuillo C, De Vito C, et al. Which BRCA genetic
testing programs are ready for implementation in health care? A
systematic review of economic evaluations. Genet Med.
2016;18:1171–80.
60. NHS UKGTN Testing Criteria. Available at https://ukgtn.nhs.uk/
ﬁleadmin/uploads/ukgtn/Documents/Resources/Library/Policies_
Procedures/Testing_Criteria_paper.pdf. Accessed 30 Oct 2017.
61. Gagnon MP, Desmartis M, Lepage-Savary D, et al. Introducing
patients’ and the public’s perspectives to health technology
assessment: a systematic review of international experiences. Int J
Technol Assess Health Care. 2011;1:31–42.
62. HIScreenDiag Report Summary. Building a tool to evaluate and
improve health investments in screening and diagnosis of disease.
2011. Available at http://cordis.europa.eu/result/rcn/56825_en.
html. Accessed 8 May 2017.
E. Pitini et al.
63. EUnetHTA Joint Action 2, Work Package 8. HTA Core Model ®
version 3.0. Available at https://www.htacoremodel.info/Brow
seModel.aspx. Accessed 8 May 2017.
64. Guyatt GH, Oxman AD, Vist GE, GRADE Working
Group. et al. GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ.
2008;336:924–6.
65. UK Genetic Testing Network. Fifth report of the UKGTN. Pro-
moting gene testing together. London, UK: UK Genetic Testing
Network; 2017.
66. Matthijs G, Dierking A, Schmidtke J. New EuroGentest/ESHG
guidelines and a new clinical utility gene card format for NGS-
based testing. Eur J Hum Genet. 2016;24:1. https://doi.org/10.
1038/ejhg.2015.229.
How is genetic testing evaluated?
